Scientific Letters
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases
First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: September 1, 2026
0
Views
0
Downloads
Authors
N/A
Downloads
Download data is not yet available.
Citations
[1] Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99:2191-2212. doi:10.1002/ajh.27443.
[2] Chinese Society of Hematology, Chinese Medical Association. Guideline for the diagnosis and treatment of chronic myeloid leukemia (2025 edition). Zhonghua Xue Ye Xue Za Zhi. 2025;46:1081-1093. doi:10.3760/cma.j.cn121090-20250923-00437.
[3] Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gokbuget N, Gotlib J, Hellstrom-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Lowenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Dohner H, Tefferi A. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200-1228. doi:10.1182/blood.2022015850.
[4] Zhang L, Meng L, Liu B, Zhang Y, Zhu H, Cui J, Sun A, Hu Y, Jin J, Jiang H, Zhang X, Li Y, Liu L, Zhang W, Liu X, Gu J, Qiao J, Ouyang G, Liu X, Luo J, Jiang M, Xie X, Li J, Zhao C, Zhang M, Yang T, Wang J. Flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: a phase III, randomized, open-label, multicenter FESTnd study. Clin Cancer Res. 2021;27:70-77. doi:10.1158/1078-0432.CCR-20-1600.
[5] Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, Liu X, Liang R, Chen C, Huang J, Zhu H, Pan L, Wang X, Li G, Liu Z, Zhang Y, Liu Z, Hu J, Liu C, Li F, Yang W, Meng L, Han Y, Lin L, Zhao Z, Tu C, Zheng C, Bai Y, Zhou Z, Chen S, Qiu H, Yang L, Sun X, Sun H, Zhou L, Liu Z, Wang D, Guo J, Pang L, Zeng Q, Suo X, Zhang W, Zheng Y, Zhang Y, Li W, Jiang Q. Comparison of the efficacy among nilotinib, dasatinib, flumatinib and imatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients: a real-world multicenter retrospective study. Clin Lymphoma Myeloma Leuk. 2024;24:e257-e266. doi:10.1016/j.clml.2024.02.008.
[6] Lei Y, Zhao X, Qiao C, Hong M, Qian S, Li J, Li W, Zhu Y. Real-world comparison of flumatinib and nilotinib as first-line therapy for patients with chronic phase chronic myeloid leukemia: a multicenter retrospective study. Ther Adv Med Oncol. 2025;17:17588359251335905. doi:10.1177/17588359251335905.
[7] Sun M, Li S, Liu Z, Ma S, Liu X, Meng Q, Zheng Y, Chen C. Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: a real-world single-center retrospective study, with a focus on premature drug discontinuation. Leuk Res. 2024;142:107507. doi:10.1016/j.leukres.2024.107507.
Ethics Approval
chronic-phase chronic myeloid leukemia; flumatinib; tyrosine kinase inhibitor; molecular response; adverse events; real-world studySupporting Agencies
N/AHow to Cite
“First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1), p. e2026066. doi:10.4084/MJHID.2026.066.
Copyright (c) 2026 Dangui Chen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
